These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 35035534)

  • 21. PD-1 Inhibitors in Elderly and Immunocompromised Patients with Advanced or Metastatic Cutaneous Squamous Cell Carcinoma.
    Yakobson A; Abu Jama A; Abu Saleh O; Michlin R; Shalata W
    Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cemiplimab in advanced cutaneous squamous cell carcinoma.
    Naik PP
    Dermatol Ther; 2021 Nov; 34(6):e15184. PubMed ID: 34716727
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cemiplimab and Cutaneous Squamous Cell Carcinoma: From Bench to Bedside.
    Goodman DT
    JPRAS Open; 2022 Sep; 33():155-160. PubMed ID: 36046255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systemic Immunotherapy for Advanced Cutaneous Squamous Cell Carcinoma.
    Ogata D; Tsuchida T
    Curr Treat Options Oncol; 2019 Mar; 20(4):30. PubMed ID: 30874952
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-Life Study of the Benefit of Concomitant Radiotherapy with Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma (cSCC): A Retrospective Cohort Study.
    Bailly-Caillé B; Kottler D; Morello R; Lecornu M; Kao W; Meyer E; Dompmartin A; L'Orphelin JM
    Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672444
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Variable Outcome of Immunotherapy in Advanced Multiple Cutaneous Squamous Cell Carcinomas in Two Patients with Recessive Dystrophic Epidermolysis Bullosa.
    Trefzer L; Hess ME; Scholten L; Technau-Hafsi K; Meiss F; Boerries M; Has C; Rafei-Shamsabadi D
    Acta Derm Venereol; 2023 Jun; 103():adv4870. PubMed ID: 37338146
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Promising Immune Treatment of Advanced Cutaneous Squamous Cell Carcinoma with Cemiplimab-Real-World Experience in the Global SARS-CoV-2 Pandemic.
    Pabianek M; Lesiak A; Nejc D; Kuncman Ł; Narbutt J; Skibińska M; Ciążyńska M
    Curr Oncol; 2022 Oct; 29(10):7794-7801. PubMed ID: 36290893
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Update on the anti-programmed cell death-1 receptor antibodies in advanced cutaneous squamous-cell carcinoma.
    Benzaquen M
    Dermatol Ther; 2020 May; 33(3):e13325. PubMed ID: 32208547
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cemiplimab: A Review in Advanced Cutaneous Squamous Cell Carcinoma.
    Lee A; Duggan S; Deeks ED
    Drugs; 2020 Jun; 80(8):813-819. PubMed ID: 32306208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-World Experience With Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma.
    Strum S; Climans S; Purcell V; Black M; Winquist E; Ernst S
    J Cutan Med Surg; 2024; 28(5):453-457. PubMed ID: 39056376
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cutaneous Squamous Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches.
    Fania L; Didona D; Di Pietro FR; Verkhovskaia S; Morese R; Paolino G; Donati M; Ricci F; Coco V; Ricci F; Candi E; Abeni D; Dellambra E
    Biomedicines; 2021 Feb; 9(2):. PubMed ID: 33572373
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cemiplimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma: Appropriate Patient Selection and Perspectives.
    Mager L; Gardeen S; Carr DR; Shahwan KT
    Clin Cosmet Investig Dermatol; 2023; 16():2135-2142. PubMed ID: 37581012
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cemiplimab in cutaneous squamous cell carcinomas (SCC): an overview and a clinical case.
    Ghidini A; Santangelo D; Vaccaro G; Chillura M; Petrelli F
    Oral Oncol; 2022 May; 128():105847. PubMed ID: 35367788
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: The Current and Future Role of Radiation Therapy in the Era of Immunotherapy.
    Ferini G; Palmisciano P; Forte S; Viola A; Martorana E; Parisi S; Valenti V; Fichera C; Umana GE; Pergolizzi S
    Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Previous radiotherapy increases the efficacy of cemiplimab in the treatment of locally advanced and metastatic cutaneous squamous cell carcinoma: A retrospective analysis.
    Nardone V; Napolitano S; Gagliardi F; Esposito A; Caraglia F; Briatico G; Scharf C; Ronchi A; D'Onofrio I; D'Ippolito E; Russo A; Belfiore MP; Franco R; Argenziano G; Ciardiello F; Reginelli A; Cappabianca S; Troiani T
    J Am Acad Dermatol; 2024 Oct; 91(4):678-683. PubMed ID: 38885840
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma.
    Ahmed SR; Petersen E; Patel R; Migden MR
    Expert Rev Clin Pharmacol; 2019 Oct; 12(10):947-951. PubMed ID: 31524530
    [No Abstract]   [Full Text] [Related]  

  • 37. Cemiplimab in an Elderly Frail Population of Patients With Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Center Real-Life Experience From Italy.
    Strippoli S; Fanizzi A; Quaresmini D; Nardone A; Armenio A; Figliuolo F; Filotico R; Fucci L; Mele F; Traversa M; De Luca F; Montagna ES; Ruggieri E; Ferraiuolo S; Macina F; Tommasi S; Sciacovelli AM; De Risi I; Albano A; Massafra R; Guida M
    Front Oncol; 2021; 11():686308. PubMed ID: 34820323
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The Cutaneous Squamous Cell Carcinoma - An Update].
    Burda B; Schultz ES
    Laryngorhinootologie; 2023 Oct; 102(10):735-741. PubMed ID: 37054747
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cemiplimab in Ultra-Octogenarian Patients with Cutaneous Squamous Cell Carcinoma: The Real-Life Experience of a Tertiary Referral Center.
    Denaro N; Passoni E; Indini A; Nazzaro G; Beltramini GA; Benzecry V; Colombo G; Cauchi C; Solinas C; Scartozzi M; Marzano AV; Garrone O
    Vaccines (Basel); 2023 Sep; 11(9):. PubMed ID: 37766176
    [TBL] [Abstract][Full Text] [Related]  

  • 40. First-line programmed death-1 inhibitor treatment for locoregionally advanced or metastatic cutaneous squamous cell carcinoma - A real-world experience from Israel.
    Averbuch I; Salman S; Shtamper N; Doweck I; Popovtzer A; Markel G; Hendler D; Finkel I; Moore A; Fenig E; Taha T; Mhameed K; Kurman N; Billan S
    Front Oncol; 2023; 13():1117804. PubMed ID: 36793605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.